Advances and challenges in experimental models for Epstein–Barr virus research
mLife · 2026-08 · 5 (4) · 401-416
DOI: 10.1002/mlf2.70081 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift mLife, online erschienen am 11.08.2026. Verfasst von Gulimire Wufuer und 5 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, Department of Laboratory Medicine, School of Public Health…. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 175 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Beijing Municipality.
Abstract (Originalsprache)
Epstein–Barr virus (EBV), the first identified human oncovirus, is a ubiquitous γ‐herpesvirus etiologically linked to diverse malignancies, lymphoproliferative disorders, and autoimmune diseases. Experimental models are pivotal for unraveling the infection and pathogenesis mechanisms, life cycle regulation, as well as development and evaluation of antiviral vaccines and therapeutics. Traditional two‐dimensional (2D) cell lines (e.g., lymphoblastoid cell lines [LCLs] and NPC43) have provided foundational insights into viral latency and oncogenesis, but lack physiological complexity. Emerging three‐dimensional (3D) models, such as air–liquid interface (ALI) cultures, spheroids, and patient‐derived organoids (PDOs), better mimic tissue architecture and tumor microenvironments and yet face challenges in scalability, dynamic microenvironments, and immune component integration. Animal models, such as humanized mice, rabbits, and tree shrews, have been developed that overcome in vitro limitations by recapitulating systemic interactions, immune responses, and disease progression. Despite these advances, persistent challenges remain, including species‐specific constraints, incomplete modeling of the tumor microenvironment, partial immune system representation, and limited disease heterogeneity. This review systematically summarizes the technical features, applicability, and limitations of current models, provides guidance for selecting experimental models in further studies, and emphasizes the need for innovative, patient‐tailored platforms to unravel EBV's lifelong pathogenesis and facilitate the translation of EBV vaccines and therapeutics.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- State Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, Department of Laboratory Medicine, School of Public Health Xiamen University Xiamen China.
- National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Collaborative Innovation Center of Biologic Products, National Innovation Platform for Industry-Education Integration in Vaccine Research…
ORCID-Profile: Tingdong Li, Jun Zhang
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Beijing Municipality
Zitieren
APA
Wufuer, G., Tang, J., Li, T., Ge, S., Zhang, J., & Xia, N. (2026). Advances and challenges in experimental models for Epstein–Barr virus research. mLife, 5(4), 401-416. https://doi.org/10.1002/mlf2.70081
Vancouver
Wufuer G, Tang J, Li T, Ge S, Zhang J, Xia N. Advances and challenges in experimental models for Epstein–Barr virus research. mLife. 2026;5(4):401-416. doi:10.1002/mlf2.70081
BibTeX
@article{Wufuer2026,
author = {Wufuer, Gulimire and Tang, Jiabao and Li, Tingdong and Ge, Shengxiang and Zhang, Jun and Xia, Ningshao},
title = {Advances and challenges in experimental models for Epstein–Barr virus research},
journal = {mLife},
year = {2026},
volume = {5},
number = {4},
pages = {401--416},
doi = {10.1002/mlf2.70081}
}
EUVIMED